Scholarlink

Purpose <p>Breast cancer is the most commonly diagnosed cancer worldwide. To evaluate the safety and efficacy of abemaciclib in combination with endocrine therapy (ET) for the treatment of Hormone Receptor/ Human Epidermal Growth Factor Receptor 2 (HR + /HER2-) advanced or metastatic breast cancer, this systematic review and meta-analysis compared several treatment regimens and patient groups.</p> Methods <p>In this systematic review and meta-analysis, we searched (PubMed, Scopus, and the Cochrane from inception to 5 April 2025) to identify the studies that compared abemaciclib plus ET to ET alone. The measure effects used were hazard ratios (HR) for overall survival (OS), progression-free survival (PFS), and invasive disease-free survival (IDFS), while risk ratios (RR) for objective response rate (ORR), clinical benefit rate (CBR), and adverse effects· Forest plots were created using a random effects model, with a <i>p</i>-value &lt; 0·05 was considered statistically significant. This study is registered on PROSPERO (CRD420251009464).</p> Results <p>We included fourteen studies comprising 16,116 patients (8592 with abemaciclib plus ET and 7524 with ET alone), abemaciclib plus ET significantly improved PFS (HR 0·54; 95% <i>CI </i>0·49–0·59, <i>p</i> = 0·00001), IDFS (HR 0·68; 95% <i>CI </i>0·59–0·78, <i>p</i> = 0·00001), ORR (RR 2·87; 95% <i>CI </i>1·85–4·44, <i>p</i> = 0·0001), and CBR (RR 1·32; 95% <i>CI </i>1·14–1·52, <i>p</i> = 0·0002), and a non-statistically significant OS (HR of 0·86; 95% <i>CI </i>0·74–1·01, <i>p</i> = 0·06). Abemaciclib increased the risk of adverse events; cardiovascular events (4·82 times), increased blood creatinine (8·51 times), nausea (1·95 times), vomiting (2·51 times), abdominal pain (2·64 times), decreased appetite (2·59 times), diarrhea (4·20 times), aspartate aminotransferase (AST) (2·15 times), alanine aminotransferase (ALT) (2·28 times), anemia (3·79 times), thrombocytopenia (5·73 times), leukopenia (5·48 times), neutropenia (8·74 times)· However, it showed a reduced risk of arthralgia (0·73 times).</p> Conclusion <p>The combination therapy provides a clinically significant improvement in survival and treatment responses, even though the toxicity is increased but manageable, and requires careful prescription.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR + and HER2-negative breast cancer; a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年12月12日

查看全文
  • Khudija Sadia,
  • Tazmeen Talia,
  • Ishtiaq Hussain,
  • Minhal Chaudhry,
  • Natalia Shahid,
  • Muhammad Khubaib Javaid,
  • Muhammad Faizan Kamil,
  • Hajra Zainab Chaudry,
  • Laiba Azhar,
  • Hamna Ahmed Khan,
  • Abdullah Ejaz,
  • Muhammad Ubaid Akram,
  • Shahmeera Mahmood,
  • Muhammad Abdul Qadeer

摘要

Purpose

Breast cancer is the most commonly diagnosed cancer worldwide. To evaluate the safety and efficacy of abemaciclib in combination with endocrine therapy (ET) for the treatment of Hormone Receptor/ Human Epidermal Growth Factor Receptor 2 (HR + /HER2-) advanced or metastatic breast cancer, this systematic review and meta-analysis compared several treatment regimens and patient groups.

Methods

In this systematic review and meta-analysis, we searched (PubMed, Scopus, and the Cochrane from inception to 5 April 2025) to identify the studies that compared abemaciclib plus ET to ET alone. The measure effects used were hazard ratios (HR) for overall survival (OS), progression-free survival (PFS), and invasive disease-free survival (IDFS), while risk ratios (RR) for objective response rate (ORR), clinical benefit rate (CBR), and adverse effects· Forest plots were created using a random effects model, with a p-value < 0·05 was considered statistically significant. This study is registered on PROSPERO (CRD420251009464).

Results

We included fourteen studies comprising 16,116 patients (8592 with abemaciclib plus ET and 7524 with ET alone), abemaciclib plus ET significantly improved PFS (HR 0·54; 95% CI 0·49–0·59, p = 0·00001), IDFS (HR 0·68; 95% CI 0·59–0·78, p = 0·00001), ORR (RR 2·87; 95% CI 1·85–4·44, p = 0·0001), and CBR (RR 1·32; 95% CI 1·14–1·52, p = 0·0002), and a non-statistically significant OS (HR of 0·86; 95% CI 0·74–1·01, p = 0·06). Abemaciclib increased the risk of adverse events; cardiovascular events (4·82 times), increased blood creatinine (8·51 times), nausea (1·95 times), vomiting (2·51 times), abdominal pain (2·64 times), decreased appetite (2·59 times), diarrhea (4·20 times), aspartate aminotransferase (AST) (2·15 times), alanine aminotransferase (ALT) (2·28 times), anemia (3·79 times), thrombocytopenia (5·73 times), leukopenia (5·48 times), neutropenia (8·74 times)· However, it showed a reduced risk of arthralgia (0·73 times).

Conclusion

The combination therapy provides a clinically significant improvement in survival and treatment responses, even though the toxicity is increased but manageable, and requires careful prescription.